Ultimovacs ASA (OSL:ULTI) Beginning Cash Position : kr266.56 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Beginning Cash Position?

Ultimovacs ASA's Beginning Cash Position for the quarter that ended in Mar. 2024 was kr266.56 Mil.

Ultimovacs ASA's quarterly Beginning Cash Position declined from Sep. 2023 (kr344.11 Mil) to Dec. 2023 (kr300.27 Mil) and declined from Dec. 2023 (kr300.27 Mil) to Mar. 2024 (kr266.56 Mil).

Ultimovacs ASA's annual Beginning Cash Position increased from Dec. 2021 (kr440.93 Mil) to Dec. 2022 (kr574.17 Mil) but then declined from Dec. 2022 (kr574.17 Mil) to Dec. 2023 (kr425.31 Mil).

Ultimovacs ASA Beginning Cash Position Historical Data

The historical data trend for Ultimovacs ASA's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Beginning Cash Position Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

115.54

399.61

440.93

574.17

425.31

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															425.31	405.53	344.11	300.27	266.56

Ultimovacs ASA Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Ultimovacs ASA Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.